Table 2.

Effect of velogenic viscerotropic (VVNDV) AF2240 and tamoxifen in mortality rate, body and tumour weight of mice

Group	Animal number			Body weight ± SD		Tumour weight (g)	Inhibition (%)
	Beginning	End	Mortality rate (%)	Beginning	End
CC	6	6	0	16.66 ± 0.70	21.26 ± 1.24 *	1.45 ± 0.43	–
CT	6	6	0	16.48 ± 0.09	20.88 ± 0.79 *	1.21 ± 0.41	16.55
CNDV
8HA NDV	6	6	0	16.77 ± 0.11	19.49 ± 0.30 *	NG #	100
16HA NDV	6	6	0	16.64 ± 0.32	19.30 ± 0.06 *	NG #	100
32HA NDV	6	6	0	16.86 ± 0.10	19.45 ± 0.10 *	NG #	100
64HA NDV	6	6	0	16.54 ± 0.31	19.66 ± 0.13 *	NG #	100
CNDV + T
8HA NDV	6	6	0	16.93 ± 0.41	19.33 ± 0.16 *	NG #	100
16HA NDV	6	6	0	16.86 ± 0.14	19.50 ± 0.30 *	NG #	100
32HA NDV	6	6	0	16.87 ± 0.06	21.00 ± 0.40 *	2.27 ± 0.28#	−56.55
64HA NDV	6	6	0	16.66 ± 0.06	20.59 ± 0.36 *	3.64 ± 0.23#	−151.03

Results expressed in mean ± S.D. *p < 0.05 compared with beginning body weight; ^#p < 0.05 compared with cancer control (CC). CT, allotransplanted + tamoxifen; CNDV, allotransplanted + virus; CNDV+T, allotransplanted + virus + Tamoxifen; NG, negative